ArticleOncology letters2026
Meta-analysis of the clinical efficacy of anti-PD-1/L1 + paclitaxel/albumin-paclitaxel + platinum vs. paclitaxel/albumin-paclitaxel + platinum in the treatment of patients with advanced non-small cell lung cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platinum-based dual-drug chemotherapy is the standard first-line treatment for non-small cell lung cancer. It inhibits tumor proliferation through cytotoxic effects. However, in clinical practice, 30-40% of patients will experience disease progression due to primary or secondary drug resistance. The present study aimed to analyze the clinical efficacy and adverse reactions of anti-PD-1/L1 + paclitaxel/albumin-paclitaxel + platinum and paclitaxel/albumin-paclitaxel + platinum in the treatment of advanced non-small cell lung cancer. Computer searches were conducted in PubMed, The Cochrane Library, EMbase, China National Knowledge Infrastructure, Wanfang Data, VIPernet and China Biology Medicine databases. Randomized controlled trials on the clinical efficacy of taxel/albumin-paclitaxel + platinum and the combination of taxel/albumin-paclitaxel + platinum immunotherapy drugs in patients with non-small cell lung cancer were collected from the establishment of the database to May 2025. Meta-analysis was conducted using RevMan 5.4 software. A total of five randomized controlled trials were included, involving a total of 3,683 patients. The meta-analysis showed that the median survival rate and the incidence of asymptomatic recurrence in the experimental group (anti-PD-1/L1 + paclitaxel/albumin-paclitaxel + platinum combined immunotherapy drugs) for the treatment of non-small cell lung cancer were higher than those in the control group (paclitaxel/albumin-paclitaxel + platinum). The median progression-free and overall survival time in the experimental group were longer than those in the control group, and the incidence of side effects was higher than that in the control group. The experimental group had advantages in treating non-small cell lung cancer during the asymptomatic remission period and prolonging survival time, but the incidence of adverse reactions decreased.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.